[1]
Nguyen G, Delarue F, Burcklé C, Bouzhir L, Giller T, Sraer JD. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. The Journal of clinical investigation. 2002 Jun:109(11):1417-27
[PubMed PMID: 12045255]
[2]
Scott BB,McGeehan GM,Harrison RK, Development of inhibitors of the aspartyl protease renin for the treatment of hypertension. Current protein
[PubMed PMID: 16787263]
[5]
Sparks MA,Crowley SD,Gurley SB,Mirotsou M,Coffman TM, Classical Renin-Angiotensin system in kidney physiology. Comprehensive Physiology. 2014 Jul;
[PubMed PMID: 24944035]
[6]
Wagner C,Pfeifer A,Ruth P,Hofmann F,Kurtz A, Role of cGMP-kinase II in the control of renin secretion and renin expression. The Journal of clinical investigation. 1998 Oct 15;
[PubMed PMID: 9788971]
[7]
Grünberger C,Obermayer B,Klar J,Kurtz A,Schweda F, The calcium paradoxon of renin release: calcium suppresses renin exocytosis by inhibition of calcium-dependent adenylate cyclases AC5 and AC6. Circulation research. 2006 Nov 24;
[PubMed PMID: 17068292]
[8]
Wright PT,Schobesberger S,Gorelik J, Studying GPCR/cAMP pharmacology from the perspective of cellular structure. Frontiers in pharmacology. 2015;
[PubMed PMID: 26236239]
Level 3 (low-level) evidence
[9]
Zivná M,Hůlková H,Matignon M,Hodanová K,Vylet'al P,Kalbácová M,Baresová V,Sikora J,Blazková H,Zivný J,Ivánek R,Stránecký V,Sovová J,Claes K,Lerut E,Fryns JP,Hart PS,Hart TC,Adams JN,Pawtowski A,Clemessy M,Gasc JM,Gübler MC,Antignac C,Elleder M,Kapp K,Grimbert P,Bleyer AJ,Kmoch S, Dominant renin gene mutations associated with early-onset hyperuricemia, anemia, and chronic kidney failure. American journal of human genetics. 2009 Aug;
[PubMed PMID: 19664745]
[12]
Sen S,Sabırlı S,Ozyiğit T,Uresin Y, Aliskiren: review of efficacy and safety data with focus on past and recent clinical trials. Therapeutic advances in chronic disease. 2013 Sep;
[PubMed PMID: 23997927]
Level 3 (low-level) evidence